(PharmaNewsWire.Com, January 12, 2017 ) According to a new market research report "Cancer Diagnostics Market by Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) - Forecast to 2020", published by MarketsandMarkets, The Cancer Diagnostics Market is expected to reach around $13.1 Billion by 2020 with a CAGR of 12.9% from 2015 to 2020. view report http://www.marketsandmarkets.com/Market-Reports/cancer-diagnostics-market-186559121.html
The global cancer diagnostics market is segmented on the basis of technology, application, and region. Based on technology, the cancer diagnostics market is categorized into platform-based and instrument-based. The instrument-based segment is expected to account for a major share of the cancer diagnostics market, by product, in 2015.
Based on the application, the cancer diagnostics market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, and others. Breast cancer application is expected to account for a major share of the cancer diagnostics market, by application in 2015.
On the basis of region, the market is divided into North America, Europe, Asia, and Rest of the World (RoW). Rest of the World comprises Latin America, Pacific countries, and Middle East and Africa. North America is expected to account for the largest share in the cancer diagnostics market, followed by Europe and Asia. However, the Asian market is slated to grow at the highest CAGR in the coming five years and serves as a revenue pocket for the companies operating in the cancer diagnostics market.
The global cancer diagnostics market is witnessing a rapid transformation owing to several technological advancements in diagnostic platforms. Moreover, the market has seen the advent of hybrid imaging instruments with enhanced accuracy, such as PET/CT and SPECT/CT. These advancements have augmented the growth of the cancer diagnostics market. However, shortage of trained and skilled personnel poses as a restraint to the market growth of cancer diagnostics. Rise in aging population and increasing cancer cases are likely to create huge opportunity for cancer diagnostics.
Some of the major players in the global Cancer Diagnostics System Market include Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (Denmark), Becton, Dickinson and Company (U.S.), GE Healthcare (U.K.), QIAGEN N.V. (Netherlands), Abbott Laboratories, Inc. (U.S.), Roche Diagnostics (Switzerland), Siemens Healthcare (Germany), Philips Healthcare (U.K.), and C.R. Bard, Inc. (U.S.), among others.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
